[go: up one dir, main page]

EA201200855A1 - Модуляторы crth2 - Google Patents

Модуляторы crth2

Info

Publication number
EA201200855A1
EA201200855A1 EA201200855A EA201200855A EA201200855A1 EA 201200855 A1 EA201200855 A1 EA 201200855A1 EA 201200855 A EA201200855 A EA 201200855A EA 201200855 A EA201200855 A EA 201200855A EA 201200855 A1 EA201200855 A1 EA 201200855A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crth2
modulators
crth2 modulators
treatment
general formula
Prior art date
Application number
EA201200855A
Other languages
English (en)
Inventor
Ара Мермерян
Бо Пэн
Колин Хадсон
Чарльз Ким
Джоэл Мур
Джейсон Роде
Кевин Спротт
Регина Грол
Такаси Накаи
Джеймс Джайа
Уилмин Бартолини
Original Assignee
Айронвуд Фармасьютикелз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200855(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Айронвуд Фармасьютикелз, Инк. filed Critical Айронвуд Фармасьютикелз, Инк.
Publication of EA201200855A1 publication Critical patent/EA201200855A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Изобретение описывает модуляторы CRTH2 и особенно антагонисты CRTH2, пригодные для лечения различных заболеваний, включая астму и респираторные расстройства. Описанные соединения соответствуют общей формуле (I)
EA201200855A 2009-12-23 2010-12-16 Модуляторы crth2 EA201200855A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28984109P 2009-12-23 2009-12-23
PCT/US2010/060671 WO2011079007A1 (en) 2009-12-23 2010-12-16 Crth2 modulators

Publications (1)

Publication Number Publication Date
EA201200855A1 true EA201200855A1 (ru) 2013-04-30

Family

ID=43735997

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200855A EA201200855A1 (ru) 2009-12-23 2010-12-16 Модуляторы crth2

Country Status (21)

Country Link
US (1) US8674115B2 (ru)
EP (1) EP2516416A1 (ru)
JP (1) JP5731538B2 (ru)
KR (1) KR20120098908A (ru)
CN (1) CN102822163B (ru)
AR (1) AR079492A1 (ru)
AU (1) AU2010333829A1 (ru)
BR (1) BR112012017756A2 (ru)
CA (1) CA2785191A1 (ru)
CL (1) CL2012001712A1 (ru)
CO (1) CO6640201A2 (ru)
CR (1) CR20120343A (ru)
EA (1) EA201200855A1 (ru)
EC (1) ECSP12011996A (ru)
MX (1) MX2012007239A (ru)
PH (1) PH12012501280A1 (ru)
SG (1) SG181900A1 (ru)
TW (1) TW201130810A (ru)
UY (1) UY33110A (ru)
WO (1) WO2011079007A1 (ru)
ZA (1) ZA201204527B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078210A1 (en) * 2010-12-08 2012-06-14 Ironwood Pharmaceuticals, Inc. Crth2 modulators and preparation thereof
US9206164B2 (en) * 2011-03-25 2015-12-08 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
WO2013155422A1 (en) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
JPWO2017104728A1 (ja) * 2015-12-16 2018-11-29 幸久 村田 食物アレルギー治療薬
PE20181803A1 (es) * 2016-04-22 2018-11-19 Astrazeneca Ab Inhibidores de mcl-1 macrociclicos para tratar el cancer
US20230192631A1 (en) * 2020-04-16 2023-06-22 Hoffmann-La Roche Inc. Biphenyl Derivatives

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ZA927272B (en) * 1991-10-29 1994-03-23 Du Pont Herbicidal triazolecarboxamides
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
HUP9802678A3 (en) 1995-06-21 1999-12-28 Shionogi & Co Bicyclic amino derivatives and pgd2 antagonist containing the same
US5859042A (en) * 1995-09-27 1999-01-12 Ono Pharmaceutical Co., Ltd. Five membered heterocyclic compounds
JP4120993B2 (ja) 1996-12-12 2008-07-16 塩野義製薬株式会社 ヘテロ環縮合ベンゼンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
JP3215441B2 (ja) 1996-12-13 2001-10-09 塩野義製薬株式会社 ベンゾチオフェンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
JP2002532406A (ja) 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2003022814A1 (en) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives
US20030055077A1 (en) 2000-04-12 2003-03-20 Jones Thomas R. Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
US20010051624A1 (en) 2000-04-12 2001-12-13 Jones Thomas R. Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1368354A1 (en) 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1424325A4 (en) 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
DK1438298T3 (da) 2001-10-22 2010-04-12 Pfizer Prod Inc Piperazin-derivater med CCR1 receptor-antagonist-aktivitet
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
PL372968A1 (en) 2002-04-08 2005-08-08 Pfizer Inc. Tropane derivatives as ccr5 modulators
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
MXPA05001781A (es) 2002-08-12 2005-04-25 Pfizer Prod Inc Formas cristalinas de [4-carbamoil -1-(3- fluorobencil)-2, 7-dihidroxi- 7-metil- octil]-amida del acido quinoxalina-2- carboxilico.
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
JP4694963B2 (ja) 2002-08-24 2011-06-08 アストラゼネカ・アクチエボラーグ ケモカインレセプター活性のモジュレーターとしてのピリミジン誘導体
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7211672B2 (en) 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040116441A1 (en) 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
US20040097554A1 (en) 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
EA011087B1 (ru) * 2002-12-20 2008-12-30 Эмджен Инк. Соединения и фармацевтические композиции для лечения воспалительных заболеваний
SE0203820D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab chemical compounds
AR042628A1 (es) 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
SE0203828D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Chemical compounds
CA2534371A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
CN1980908A (zh) 2004-05-29 2007-06-13 7Tm制药联合股份有限公司 取代的噻唑乙酸作为crth2配体
CA2568766A1 (en) * 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
EP1758874A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Substituted thiazoleacetic acids as crth2 ligands
EP1758571A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for therapeutic use
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US7999119B2 (en) * 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
EP2268281A4 (en) * 2008-02-15 2012-05-02 Abbott Lab THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS

Also Published As

Publication number Publication date
AR079492A1 (es) 2012-02-01
BR112012017756A2 (pt) 2016-04-19
KR20120098908A (ko) 2012-09-05
PH12012501280A1 (en) 2013-02-04
WO2011079007A1 (en) 2011-06-30
JP2013515726A (ja) 2013-05-09
US20110150834A1 (en) 2011-06-23
MX2012007239A (es) 2012-10-15
CN102822163A (zh) 2012-12-12
AU2010333829A1 (en) 2012-07-12
ECSP12011996A (es) 2012-10-30
UY33110A (es) 2011-07-29
ZA201204527B (en) 2013-09-25
CL2012001712A1 (es) 2012-12-07
EP2516416A1 (en) 2012-10-31
JP5731538B2 (ja) 2015-06-10
SG181900A1 (en) 2012-08-30
CR20120343A (es) 2013-01-25
US8674115B2 (en) 2014-03-18
TW201130810A (en) 2011-09-16
CN102822163B (zh) 2016-01-20
CA2785191A1 (en) 2011-06-30
CO6640201A2 (es) 2013-03-22

Similar Documents

Publication Publication Date Title
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
EA201101182A1 (ru) Новые аминоазагетероциклические карбоксамиды
EA020330B3 (ru) Хиназолиновые соединения
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
UA110612C2 (ru) Производные 1-амино-2-циклопропилетилбороновои кислоты
JO3131B1 (ar) مركبات كيميائية
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201171081A1 (ru) Производные индола в качестве антагонистов рецептора crth2
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EP2282795A4 (en) TREATMENT OF RESPIRATORY DISEASES
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
ATE541832T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos